Streetbeat News

Price Targets

DCTH

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Delcath Systems (NASDAQ:DCTH) and raises the price target from $17 to $18.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:28 pm

VTSI

Roth MKM analyst Richard Baldry maintains a 'Buy' rating on VirTra (NASDAQ:VTSI) and raises the price target from $13 to $14.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:28 pm

VVI

B. Riley Securities analyst Bryan Maher maintains a Buy rating on Viad (NYSE:VVI) and raises the price target from $13 to $14.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:26 pm

CSSE

Chicken Soup For The Soul Entertainment (CSSE) reported worse-than-expected Q2 revenue results, leading to a drop in its share price. Multiple firms also downgraded the stock and lowered their price targets.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:21 pm

VIRX

SVB Securities analyst Andrew Berens has maintained an 'Outperform' rating on Viracta Therapeutics (NASDAQ:VIRX), but lowered the price target from $10 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:17 pm

TGAN

B. Riley Securities analyst Craig Ellis has maintained a Neutral rating on Transphorm (NASDAQ:TGAN) and lowered the price target from $4.5 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:16 pm

VERV

Guggenheim analyst Seamus Fernandez maintains a Buy rating on Verve Therapeutics (NASDAQ:VERV) but lowers the price target from $56 to $55.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 3:09 pm

OPRX

Lake Street analyst Eric Martinuzzi has maintained a 'Buy' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $18 to $13.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 3:08 pm

OPRX

Roth MKM analyst Richard Baldry has maintained a 'Buy' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $31 to $20.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 3:06 pm

VIRI

Zacks Small-Cap Research has set a price valuation of $3.50 for Virios Therapeutics. This valuation is highly dependent on the continued clinical success of IMC-1 and will be adjusted based on future clinical results.

Portfolio Pulse from Happy Mohamed

August 15, 2023 | 3:06 pm